Detailed information for compound 347470

Basic information

Technical information
  • TDR Targets ID: 347470
  • Name: tert-butyl N-[(1S,4S,7S)-7-[(1S,3R)-4-[[(2S)- 1-(benzylamino)-3-methyl-1-oxobutan-2-yl]amin o]-1-hydroxy-3-methyl-4-oxobutyl]-4-methyl-2, 5-dioxo-3,6-diazacyclotridec-1-yl]carbamate
  • MW: 645.83 | Formula: C34H55N5O7
  • H donors: 6 H acceptors: 6 LogP: 4.17 Rotable bonds: 15
    Rule of 5 violations (Lipinski): 3
  • SMILES: O=C(OC(C)(C)C)N[C@H]1CCCCCC[C@H](NC(=O)[C@@H](NC1=O)C)[C@H](C[C@H](C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C)C)O
  • InChi: 1S/C34H55N5O7/c1-21(2)28(32(44)35-20-24-15-11-10-12-16-24)39-29(41)22(3)19-27(40)25-17-13-8-9-14-18-26(38-33(45)46-34(5,6)7)31(43)36-23(4)30(42)37-25/h10-12,15-16,21-23,25-28,40H,8-9,13-14,17-20H2,1-7H3,(H,35,44)(H,36,43)(H,37,42)(H,38,45)(H,39,41)/t22-,23+,25+,26+,27+,28+/m1/s1
  • InChiKey: YQCZIMYKFGVRCA-DPWFGKHQSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • tert-butyl N-[(1S,4S,7S)-7-[(1S,3R)-4-[[(1S)-1-(benzylcarbamoyl)-2-methyl-propyl]amino]-1-hydroxy-3-methyl-4-oxo-butyl]-4-methyl-2,5-dioxo-3,6-diazacyclotridec-1-yl]carbamate
  • N-[(1S,4S,7S)-7-[(1S,3R)-4-[[(1S)-1-[(benzylamino)-oxomethyl]-2-methylpropyl]amino]-1-hydroxy-3-methyl-4-oxobutyl]-4-methyl-2,5-dioxo-3,6-diazacyclotridec-1-yl]carbamic acid tert-butyl ester
  • tert-butyl N-[(1S,4S,7S)-7-[(1S,3R)-1-hydroxy-3-methyl-4-[[(2S)-3-methyl-1-oxo-1-(phenylmethylamino)butan-2-yl]amino]-4-oxo-butyl]-4-methyl-2,5-dioxo-3,6-diazacyclotridec-1-yl]carbamate
  • N-[(1S,4S,7S)-7-[(1S,3R)-4-[[(1S)-1-(benzylcarbamoyl)-2-methyl-propyl]amino]-1-hydroxy-4-keto-3-methyl-butyl]-2,5-diketo-4-methyl-3,6-diazacyclotridec-1-yl]carbamic acid tert-butyl ester
  • tert-butyl N-[(3S,6S,13S)-13-[(1S,3R)-1-hydroxy-3-methyl-4-[[(2S)-3-methyl-1-oxo-1-(phenylmethylamino)butan-2-yl]amino]-4-oxobutyl]-3-methyl-2,5-dioxo-1,4-diazacyclotridec-6-yl]carbamate
  • tert-butyl N-[(3S,6S,13S)-13-[(1S,3R)-1-hydroxy-3-methyl-4-[[(1S)-2-methyl-1-(phenylmethylcarbamoyl)propyl]amino]-4-oxo-butyl]-3-methyl-2,5-dioxo-1,4-diazacyclotridec-6-yl]carbamate
  • N-[(3S,6S,13S)-13-[(1S,3R)-1-hydroxy-3-methyl-4-[[(1S)-2-methyl-1-[oxo-(phenylmethylamino)methyl]propyl]amino]-4-oxobutyl]-3-methyl-2,5-dioxo-1,4-diazacyclotridec-6-yl]carbamic acid tert-butyl ester
  • N-[(3S,6S,13S)-13-[(1S,3R)-4-[[(1S)-1-(benzylcarbamoyl)-2-methyl-propyl]amino]-1-hydroxy-4-keto-3-methyl-butyl]-2,5-diketo-3-methyl-1,4-diazacyclotridec-6-yl]carbamic acid tert-butyl ester
  • tert-butyl N-[(3S,6S,13S)-13-[(1S,3R)-1-hydroxy-3-methyl-4-[[(2S)-3-methyl-1-oxo-1-(phenylmethylamino)butan-2-yl]amino]-4-oxo-butyl]-3-methyl-2,5-dioxo-1,4-diazacyclotridec-6-yl]carbamate

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens beta-site APP-cleaving enzyme 1 Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Schistosoma japonicum ko:K07747 beta-site APP-cleaving enzyme 2 (memapsin 1) [EC3.4.23.45], putative Get druggable targets OG5_135830 All targets in OG5_135830
Schistosoma mansoni memapsin-2 (A01 family) Get druggable targets OG5_135830 All targets in OG5_135830
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Plasmodium falciparum plasmepsin VII beta-site APP-cleaving enzyme 1 401 aa 352 aa 21.3 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Mycobacterium tuberculosis Probable thymidylate synthase ThyA (ts) (TSASE) 0.0159 0.0608 0.0608
Chlamydia trachomatis dihydrofolate reductase 0.0879 1 0.5
Onchocerca volvulus 0.0159 0.0608 1
Mycobacterium ulcerans dihydrofolate reductase DfrA 0.0879 1 1
Echinococcus granulosus thymidylate synthase 0.0159 0.0608 0.0608
Trypanosoma brucei dihydrofolate reductase-thymidylate synthase 0.0495 0.499 1
Plasmodium falciparum bifunctional dihydrofolate reductase-thymidylate synthase 0.0495 0.499 1
Trichomonas vaginalis dihydrofolate synthase/folylpolyglutamate synthase, putative 0.0112 0 0.5
Mycobacterium ulcerans thymidylate synthase 0.0159 0.0608 0.0608
Schistosoma mansoni dihydrofolate reductase 0.0879 1 1
Plasmodium vivax bifunctional dihydrofolate reductase-thymidylate synthase, putative 0.0495 0.499 1
Mycobacterium leprae DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) 0.0879 1 1
Schistosoma mansoni bifunctional dihydrofolate reductase-thymidylate synthase 0.0159 0.0608 0.0608
Treponema pallidum folylpolyglutamate synthetase (folC) 0.0112 0 0.5
Mycobacterium leprae PROBABLE THYMIDYLATE SYNTHASE THYA (TS) (TSASE) 0.0159 0.0608 0.0608
Brugia malayi thymidylate synthase 0.0159 0.0608 0.0608
Echinococcus multilocularis dihydrofolate reductase 0.0879 1 1
Echinococcus granulosus dihydrofolate reductase 0.0879 1 1
Loa Loa (eye worm) thymidylate synthase 0.0159 0.0608 0.0608
Brugia malayi Dihydrofolate reductase 0.0879 1 1
Loa Loa (eye worm) dihydrofolate reductase 0.0879 1 1
Schistosoma mansoni memapsin-2 (A01 family) 0.0521 0.5332 0.5332
Toxoplasma gondii bifunctional dihydrofolate reductase-thymidylate synthase 0.0495 0.499 1
Leishmania major dihydrofolate reductase-thymidylate synthase 0.0495 0.499 1
Mycobacterium tuberculosis Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) 0.0879 1 1
Trypanosoma cruzi dihydrofolate reductase-thymidylate synthase 0.0495 0.499 1
Echinococcus multilocularis thymidylate synthase 0.0159 0.0608 0.0608

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 0.285 uM Inhibition of recombinant human BACE1 in FRET assay ChEMBL. 16249081
IC50 (binding) = 0.285 uM Inhibition of recombinant human BACE1 in FRET assay ChEMBL. 16249081
IC50 (functional) > 100 uM Inhibition of Abeta peptide production in HEK293 cells overexpressing APP751swe ChEMBL. 16249081

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.